September 15, 2026 · Phase 2 readout
MGNX Phase 2 readout: a neutral outcome, -3.8%
On September 15, 2026, lorigerlimab — MacroGenics, Inc. (Androgen-Independent Prostatic Cancer) reached its Phase 2 readout. The result was a neutral outcome, and the stock moved -3.8% in the window around the event. It had already run -5.2% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$4.20
1d before
$4.04
Event day
$4.08
1d after
$4.14
5d after
Our prediction vs. the result
CatalystAlert called this one neutral (+0.3% expected); the stock actually moved -3.8%. Model confidence at the time: 200%.
See the full scored track recordPre-catalyst setup
-5.2%
30-day run-up
4885%
30-day volatility
0.9×
volume spike